Eli Lilly and Company (NYSE:LLY) Shares Acquired by Meadow Creek Wealth Advisors LLC

Meadow Creek Wealth Advisors LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 112.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,161 shares of the company’s stock after acquiring an additional 2,202 shares during the quarter. Eli Lilly and Company makes up 2.3% of Meadow Creek Wealth Advisors LLC’s investment portfolio, making the stock its 8th biggest holding. Meadow Creek Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $3,237,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Lipe & Dalton purchased a new position in Eli Lilly and Company during the 4th quarter worth approximately $26,000. Core Wealth Advisors Inc. grew its stake in Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the last quarter. Tidemark LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth approximately $29,000. Redmont Wealth Advisors LLC purchased a new position in Eli Lilly and Company during the 1st quarter worth approximately $40,000. Finally, Frank Rimerman Advisors LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth approximately $37,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 0.9 %

LLY opened at $898.10 on Friday. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The business has a 50 day simple moving average of $824.60 and a 200-day simple moving average of $746.69. The stock has a market capitalization of $853.56 billion, a P/E ratio of 132.27, a P/E/G ratio of 1.96 and a beta of 0.41. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $918.50.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company’s revenue was up 26.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.62 earnings per share. On average, equities analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.58%. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research reports. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Citigroup raised their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. BMO Capital Markets reiterated an “outperform” rating and issued a $1,001.00 target price on shares of Eli Lilly and Company in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday. Finally, JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $812.72.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 92,563 shares of the firm’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the transaction, the insider now owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 858,742 shares of company stock valued at $735,573,781. 0.13% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.